Particles formed by polymeric adjuvants preferentially localize to the lymph node and elicit robust immunity.
This is a preview of subscription content, access via your institution
Relevant articles
Open Access articles citing this article.
-
A nanoscale metal organic frameworks-based vaccine synergises with PD-1 blockade to potentiate anti-tumour immunity
Nature Communications Open Access 31 July 2020
Access options
Subscribe to this journal
Receive 12 print issues and online access
$209.00 per year
only $17.42 per issue
Buy this article
- Purchase on Springer Link
- Instant access to full article PDF
Prices may be subject to local taxes which are calculated during checkout
References
Lynn, G.M. et al. Nat. Biotechnol. 33, 1201–1210 (2015).
Steinhagen, F., Kinjo, T., Bode, C. & Klinman, D.M. Vaccine 29, 3341–3355 (2011).
Vasilakos, J.P. & Tomai, M.A. Expert Rev. Vaccines 12, 809–819 (2013).
Kawai, T. & Akira, S. Immunity 34, 637–650 (2011).
Lizée, G. et al. Annu. Rev. Med. 64, 71–90 (2013).
Wu, T.Y. et al. Sci. Transl. Med. 6, 263ra160 (2014).
Hanson, M.C. et al. J. Clin. Invest. 125, 2532–2546 (2015).
Kopeček, J. & Kopečková, P. Adv. Drug Deliv. Rev. 62, 122–149 (2010).
Park, H. et al. J. Immunol. 190, 4103–4115 (2013).
Author information
Authors and Affiliations
Corresponding author
Ethics declarations
Competing interests
The authors declare no competing financial interests.
Rights and permissions
About this article
Cite this article
Dane, E., Irvine, D. Big thinking for adjuvants. Nat Biotechnol 33, 1146–1148 (2015). https://doi.org/10.1038/nbt.3398
Published:
Issue Date:
DOI: https://doi.org/10.1038/nbt.3398
This article is cited by
-
A nanoscale metal organic frameworks-based vaccine synergises with PD-1 blockade to potentiate anti-tumour immunity
Nature Communications (2020)